

**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use Simcor safely and effectively. See full prescribing information for Simcor.

**Simcor (simvastatin/niacin extended-release) Tablet, Film Coated, Extended Release for Oral use**  
**Initial U.S. Approval: 2008**

**INDICATIONS AND USAGE**

SIMCOR is a combination of simvastatin, an HMG-Co-A reductase inhibitor, and extended-release niacin (Niaspan), nicotinic acid. SIMCOR is indicated to:

- Reduce elevated total-C, LDL-C, Apo B, non-HDL-C, TG, or to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia when treatment with simvastatin monotherapy or niacin extended-release monotherapy is considered inadequate. (1.1)
- Reduce TG in patients with hypertriglyceridemia (Fredrickson type IV hyperlipidemia) when treatment with simvastatin monotherapy or niacin extended-release monotherapy is considered inadequate. (1.1)

Limitations of use:

No incremental benefit of SIMCOR on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin monotherapy and niacin monotherapy has been established. (1.1)

**DOSAGE AND ADMINISTRATION**

- SIMCOR should be taken at bedtime with a low-fat snack. (2)
- Dose range: 500/20 mg to 2000/40 mg once daily. (2)
- Initial dose for patients naïve to or switching from immediate-release niacin: 500/20 mg once daily. (2)
- The initial dose for patients already receiving niacin extended-release should not exceed 2000/40 mg once daily. (2)
- Maintenance dose: 1000/20 mg to 2000/40 mg once daily. (2)
- Doses greater than 2000/40 mg daily are not recommended. (2)

**DOSAGE FORMS AND STRENGTHS**

- Unscored film-coated tablets:  
500 mg niacin extended-release/20 mg simvastatin (3)  
750 mg niacin extended-release/20 mg simvastatin (3)  
1000 mg niacin extended-release/20 mg simvastatin (3)

**CONTRAINDICATIONS**

- Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels (4, 5.2)
- Active peptic ulcer disease (4)
- Arterial bleeding (4)
- Women who are pregnant or may become pregnant (4, 8.1)
- Nursing mothers (4, 8.3)
- Known hypersensitivity to product components (4, 6.1)

**WARNINGS AND PRECAUTIONS**

- Skeletal muscle effects (e.g., myopathy and rhabdomyolysis): Risks increase with higher doses, advanced age ( $\geq 65$ ), hypothyroidism, renal impairment, and concomitant use of cyclosporine, danazol, gemfibrozil, amiodarone, and verapamil and potent CYP3A4 inhibitors. (5.1)
- Liver enzyme abnormalities and monitoring: Persistent elevations in hepatic transaminase can occur. Monitor liver enzymes before and during treatment. (5.2)
- Severe hepatic toxicity has occurred in patients substituting sustained-release niacin for immediate-release niacin at equivalent doses. If switching from other niacin preparations, initiate with lowest SIMCOR dose; niacin extended-release can be converted at equivalent doses. (5.2)
- Niacin extended-release can increase serum glucose levels. Glucose levels should be closely monitored in diabetic or potentially diabetic patients particularly during the first few months of use. (5.3)

**ADVERSE REACTIONS**

The most common (incidence > 3%) adverse reactions with SIMCOR are flushing, headache, back pain, diarrhea, nausea, and pruritis. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Abbott Laboratories at 1-800-633-9110 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch)

**DRUG INTERACTIONS**

- Potent inhibitors of CYP 3A4: Combination increases simvastatin exposure. SIMCOR should not be used with potent inhibitors of CYP3A4. (7.1)
- Cyclosporine: Combination with SIMCOR should be avoided. (7.2)
- Danazol: Combination with SIMCOR should be avoided. (7.2)
- Amiodarone: Combination with SIMCOR should be limited to the 20 mg once daily dose of simvastatin. (7.3)
- Verapamil: Combination with SIMCOR should be limited to the 20 mg once daily dose of simvastatin. (7.3)
- Gemfibrozil: Combination with SIMCOR should be avoided. (7.4)
- Fenofibrate: Combination with SIMCOR should be avoided. (7.4)
- Coumarin anticoagulants: Combination prolongs INR. Achieve stable INR prior to starting SIMCOR. Monitor INR frequently until stable upon initiation or alteration of SIMCOR therapy. (7.7)

**USE IN SPECIFIC POPULATIONS**

- Severe renal impairment (not on dialysis): SIMCOR should be used with extreme caution. (8.7)

See 17 for PATIENT COUNSELING INFORMATION

**FULL PRESCRIBING INFORMATION: CONTENTS\***

**1 INDICATIONS AND USAGE**

- 1.1 Patients with Hypercholesterolemia Requiring Modifications of Lipid Profiles

**2 DOSAGE AND ADMINISTRATION**

**3 DOSAGE FORMS AND STRENGTHS**

**4 CONTRAINDICATIONS**

**5 WARNINGS AND PRECAUTIONS**

- 5.1 Myopathy/Rhabdomyolysis
- 5.2 Liver Dysfunction
- 5.3 Laboratory Abnormalities

**6 ADVERSE REACTIONS**

- 6.1 Clinical Studies Experience

**7 DRUG INTERACTIONS**

- 7.1 CYP3A4 Inhibitors
- 7.2 Cyclosporine or Danazol
- 7.3 Amiodarone or Verapamil
- 7.4 Gemfibrozil and other Fibrates
- 7.5 Propranolol
- 7.6 Digoxin
- 7.7 Coumarin Anticoagulants
- 7.8 Aspirin
- 7.9 Antihypertensive Therapy
- 7.10 Bile Acid Sequestrants
- 7.11 Other

**8 USE IN SPECIFIC POPULATIONS**

- 8.1 Pregnancy
- 8.3 Nursing Mothers
- 8.4 Pediatric Use

- 8.5 Geriatric Use

- 8.6 Gender

- 8.7 Renal Impairment

- 8.8 Hepatic Impairment

**10 OVERDOSAGE**

**11 DESCRIPTION**

**12 CLINICAL PHARMACOLOGY**

- 12.1 Mechanism of Action

- 12.2 Pharmacodynamics

- 12.3 Pharmacokinetics

**13 NONCLINICAL TOXICOLOGY**

- 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

- 13.2 Animal Toxicology and/or Pharmacology

**14 CLINICAL STUDIES**

- 14.1 Modifications of Lipid Profiles

**16 HOW SUPPLIED/STORAGE AND HANDLING**

**17 PATIENT COUNSELING INFORMATION**

- 17.1 Dosing Time

- 17.2 Tablet Integrity

- 17.3 Dosing Interruption

- 17.4 Muscle Pain

- 17.5 Flushing

- 17.6 Use of Aspirin or other Non-Inflammatory Medication

- 17.7 Diet

- 17.8 Supplements

- 17.9 Dizziness

- 17.10 Diabetics

- 17.11 Pregnancy

- 17.12 Breastfeeding

\* Sections or subsections omitted from the full prescribing information are not listed

---

**FULL PRESCRIBING INFORMATION**

**1 INDICATIONS AND USAGE**

Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.

### 1.1 Patients with Hypercholesterolemia Requiring Modifications of Lipid Profiles

#### SIMCOR

SIMCOR is indicated to reduce total-C, LDL-C, Apo B , non-HDL-C, or TG, or to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson type IIa and IIb) when treatment with simvastatin monotherapy or niacin extended-release monotherapy is considered inadequate.

SIMCOR is indicated to reduce TG in patients with hypertriglyceridemia (Fredrickson type IV hyperlipidemia) when treatment with simvastatin monotherapy or niacin extended-release monotherapy is considered inadequate.

#### Limitations of use

No incremental benefit of SIMCOR on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin monotherapy and niacin monotherapy has been established.

## 2 DOSAGE AND ADMINISTRATION

SIMCOR should be taken as a single daily dose at bedtime, with a low fat snack. Patients not currently on niacin extended-release and patients currently on niacin products other than niacin extended-release should start SIMCOR at a single 500/20 mg tablet daily at bedtime [*See Warnings and Precautions ( 5.2)*]. The dose of niacin extended-release should not be increased by more than 500 mg daily every 4 weeks - see Table 1. The recommended maintenance dose for SIMCOR is 1000/20 mg to 2000/40 mg (two 1000/20 tablets) once daily depending on patient tolerability and lipid levels. The efficacy and safety of doses of SIMCOR greater than 2000/40 mg daily have not been studied and are therefore not recommended. If SIMCOR therapy is discontinued for an extended period of time (> 7 days), re-titration as tolerated is recommended. SIMCOR tablets should be taken whole and should not be broken, crushed, or chewed before swallowing.

Table 1. Recommended niacin extended-release dosing

---

	Week(s)	Daily dose of niacin extended-release
Initial Titration Schedule	1 to 4	500 mg
	5 to 8	1000 mg
	*	1500 mg
	*	2000 mg
* After Week 8, titrate to patient response and tolerance. If response to 1000 mg daily is inadequate, increase dose to 1500 mg daily; may subsequently increase dose to 2000 mg daily. Daily dose should not be increased more than 500 mg in a 4-week period, and doses above 2000 mg daily are not recommended.		

Due to the increased risk of hepatotoxicity with other modified-release (sustained-release or time-release) niacin preparations or immediate-release (crystalline) niacin, SIMCOR should only be substituted for equivalent doses of niacin extended-release (NIASPAN).

Flushing [*See Adverse Reactions (6.1)*] may be reduced in frequency or severity by pretreatment with aspirin or other non-steroidal anti-inflammatory drugs (approximately 30 minutes prior to SIMCOR dose). Flushing, pruritus, and gastrointestinal distress are also reduced by gradually increasing the dose of niacin (refer to Table 1) and avoiding administration on an empty stomach.

### 3 DOSAGE FORMS AND STRENGTHS

SIMCOR tablets are formulated for oral administration in the following strength combinations:

**Table 2. SIMCOR Tablet Strengths**

	500mg/20mg	750mg/20mg	1000mg/20mg
Niacin extended-release equivalent (mg)	500	750	1000
simvastatin equivalent (mg)	20	20	20

- 500 mg/20 mg blue unscored tablets debossed with 021 on one side and KOS on the other
- 750 mg/20 mg blue unscored tablets debossed with 022 on one side and KOS on the other
- 1000 mg/20 mg blue unscored tablets debossed with 023 on one side and KOS on the other

### 4 CONTRAINDICATIONS

SIMCOR is contraindicated in the following conditions:

- Active liver disease, which may include unexplained persistent elevations in hepatic transaminase levels [*See Warnings and Precautions ( 5.2)*]
- Patients with active peptic ulcer disease
- Patients with arterial bleeding
- Women who are pregnant or may become pregnant. SIMCOR may cause fetal harm when administered to a pregnant woman. Serum cholesterol and triglycerides increase during normal pregnancy, and cholesterol or cholesterol derivatives are essential for fetal development. Atherosclerosis is a chronic process and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary hypercholesterolemia therapy. There are no adequate and well-controlled studies of SIMCOR use during pregnancy; however in rare reports congenital anomalies were observed following intrauterine exposure to HMG-CoA reductase inhibitors. In rat and rabbit animal reproduction studies, simvastatin revealed no evidence of teratogenicity. There are no animal reproductive studies conducted with niacin. If SIMCOR is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. [*See Use In Specific Populations (8.1)*]
- Nursing mothers. SIMCOR contains simvastatin and nicotinic acid. Nicotinic acid is excreted into human milk and it is not known whether simvastatin is excreted into human milk; however a small amount of another drug in this class does pass into breast milk. Because of the potential for serious adverse reactions in nursing infants, women who require SIMCOR treatment should not breastfeed their infants. [*See Use In Specific Populations (8.3)*]
- Patients with a known hypersensitivity to any component of this product. Hypersensitivity reactions including one of more of the following adverse reactions have been reported for simvastatin and/or niacin extended-release: anaphylaxis, angioedema, urticaria, fever, dyspnea, tongue edema, larynx edema, face edema, peripheral edema, laryngismus, and flushing. [*See Adverse Reactions (6.1)*]

## 5 WARNINGS AND PRECAUTIONS

SIMCOR should not be substituted for equivalent doses of immediate-release (crystalline) niacin. For patients switching from immediate-release niacin to SIMCOR, therapy with SIMCOR should be initiated at 500/20 mg and appropriately titrated to the desired therapeutic response. Doses of SIMCOR greater than 2000/40 mg are not recommended.

## 5.1 Myopathy/Rhabdomyolysis

### Simvastatin

Simvastatin, like other inhibitors of HMG-CoA reductase, occasionally causes myopathy manifested as muscle pain, tenderness or weakness with creatine kinase (CK) above ten times the upper limit of normal (ULN). Myopathy sometimes takes the form of rhabdomyolysis with or without acute renal failure secondary to myoglobinuria, and rare fatalities have occurred. The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.

As with other HMG-CoA reductase inhibitors, the risk of myopathy/rhabdomyolysis is dose related. In a clinical trial database in which 41,050 patients were treated with simvastatin with 24,747 (approximately 60%) treated for at least 4 years, the incidence of myopathy was approximately 0.02%, 0.08%, and 0.53% at 20, 40, and 80 mg/day, respectively. In these trials, patients were carefully monitored and some interacting medicinal products were excluded.

Potent inhibitors of CYP3A4: The risk of myopathy appears to be increased by high levels of HMG-CoA reductase inhibitory activity in plasma. Simvastatin is metabolized by the cytochrome P450 isoform 3A4. Certain drugs which share this metabolic pathway can raise the plasma levels of simvastatin and may increase the risk of myopathy. These include cyclosporine, itraconazole, ketoconazole, and other antifungal azoles, the macrolide antibiotics erythromycin and clarithromycin, and the ketolide antibiotic telithromycin, HIV protease inhibitors, the antidepressant nefazodone, or large quantities of grapefruit juice (> 1 quart daily).

The risk of myopathy/rhabdomyolysis is increased by concomitant use of simvastatin and, therefore, SIMCOR with the following:

*Potent inhibitors of cytochrome P-450 isoform, 3A4 (CYP 3A4):*

*Itraconazole, ketoconazole, and other antifungal azoles*

*Macrolide antibiotics erythromycin, clarithromycin, and telithromycin*

*HIV protease inhibitors*

*Antidepressant nefazodone*

*Grapefruit juice in large quantities (> 1 quart daily)*

The use of SIMCOR concomitantly with these potent CYP3A4 inhibitors should be avoided. [See *Drug Interactions (7.1)*]

*Cyclosporine or Danazol:* Simvastatin dose should not exceed 10 mg daily in combination with cyclosporine or danazol. Therefore, the combined use of SIMCOR with cyclosporine or danazol should be avoided. [See *Drug Interactions (7.2)*]

*Gemfibrozil:* Simvastatin dose should not exceed 10 mg daily when concomitantly used with gemfibrozil. Therefore, the combined use of SIMCOR with gemfibrozil should be avoided. [See *Drug Interactions (7.4)*]

*Other Fibrates:* Combined use of SIMCOR with drugs that cause myopathy/rhabdomyolysis when given alone, such as fibrates, should be avoided. [See *Drug Interactions (7.4)*]

*Amiodarone or Verapamil:* The dose of the simvastatin component of SIMCOR should not exceed 20 mg in patients receiving amiodarone or verapamil concomitantly. The combined use of the simvastatin at doses higher than 20 mg daily with amiodarone or verapamil should be avoided unless the clinical benefit is likely to outweigh the increased risk of myopathy. [See *Drug Interactions (7.3)*]

## **SIMCOR**

Myopathy and/or rhabdomyolysis have been reported when simvastatin is used in combination with lipid-altering doses ( $\geq 1$  gram/day) of niacin. Physicians contemplating the use of SIMCOR, a combination of simvastatin and niacin, should weigh the potential benefits and risks, and should carefully monitor for any signs and symptoms of muscle pain, tenderness, or weakness, particularly during the initial month of treatment or during any period of upward dosage titration of either drug. Periodic determination of serum creatine kinase (CK) determinations may be considered in such situations, but there is no assurance that such monitoring will prevent myopathy.

Patients starting therapy with SIMCOR should be advised of the risk of myopathy, and told to report promptly unexplained muscle pain, tenderness, or weakness. A CK level above 10 times ULN in a patient with unexplained muscle symptoms indicates myopathy. SIMCOR therapy should be discontinued if myopathy is diagnosed or suspected.

In patients with complicated medical histories predisposing to rhabdomyolysis, such as renal insufficiency, dose escalation requires caution. Also, as there are no known adverse consequences of brief interruption of therapy, treatment with SIMCOR should be stopped for a few days before elective

major surgery and when any major acute medical or surgical condition supervenes (e.g., sepsis, hypotension, dehydration, major surgery, trauma, severe metabolic, endocrine, and electrolyte disorders, or uncontrolled seizures).

## 5.2 Liver Dysfunction

Cases of severe hepatic toxicity, including fulminant hepatic necrosis, have occurred in patients who have substituted sustained-release (modified-release, timed-release) niacin products for immediate-release (crystalline) niacin at equivalent doses. Patients previously receiving niacin products other than niacin extended-release should be started on SIMCOR at the lowest recommended starting dose. *[See Dosage and Administration (2)]*

SIMCOR should be used with caution in patients who consume substantial quantities of alcohol and/or have a past history of liver disease. Active liver disease or unexplained transaminase elevations are contraindications to the use of SIMCOR. *[See Contraindications (4)]*

Niacin extended-release and simvastatin can cause abnormal liver tests. In a simvastatin-controlled, 24 week study with SIMCOR in 641 patients, there were no persistent increases (to more than 3x the ULN) in serum transaminases. In three placebo-controlled clinical studies of extended-release niacin there were no patients with normal serum transaminases levels at baseline who experienced elevations to more than 3x the ULN. Persistent increases (to more than 3x the ULN) in serum transaminases have occurred in approximately 1% of patients who received simvastatin in clinical studies. When drug treatment was interrupted or discontinued in these patients, the transaminases levels usually fell slowly to pretreatment levels. The increases were not associated with jaundice or other clinical signs or symptoms. There was no evidence of hypersensitivity.

Liver function tests should be performed on all patients during therapy with SIMCOR. It is recommended that liver function tests be performed before treatment begins, every 12 weeks for the first 6 months, and periodically thereafter (e.g., at approximately 6-month intervals). Patients who develop increased transaminase levels should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality returns to normal. Should an increase in transaminase levels of more than 3x ULN persist, or if transaminase elevations are associated with symptoms of nausea, fever, and/or malaise, withdrawal of SIMCOR therapy is recommended.

## 5.3 Laboratory Abnormalities



DN1744V1-Simcor-ADRChange-clean-041508

*Increase in Blood Glucose:* Niacin treatment can increase fasting blood glucose. In a simvastatin-controlled, 24-week study with SIMCOR the change from baseline in glycosylated hemoglobin levels was 0.2% for SIMCOR-treated patients and 0.2% for simvastatin-treated patients. Diabetic or potentially diabetic patients should be observed closely during treatment with SIMCOR, particularly during the first few months of therapy. Adjustment of diet and/or hypoglycemic therapy or discontinuation of SIMCOR may be necessary.

*Reduction in platelet count:* Niacin can reduce platelet count. In a simvastatin-controlled, 24-week study with SIMCOR the mean percent change from baseline for patients treated with 2000/40 mg daily was -5.6%.

*Increase in Prothrombin Time (PT):* Niacin can cause small increases in PT. In a simvastatin-controlled, 24-week study with SIMCOR this effect was not seen.

*Increase in Uric Acid:* Elevated uric acid levels have occurred with niacin therapy. In a simvastatin-controlled, 24-week study with SIMCOR this effect was not seen. Nevertheless, in patients predisposed to gout, SIMCOR therapy should be used with caution.

*Decrease in Phosphorus:* Small dose-related reductions in phosphorous levels were seen in clinical studies with niacin. In a simvastatin-controlled, 24-week study with SIMCOR this effect was not seen.

## 6 ADVERSE REACTIONS

### Overview

In a controlled clinical study, 14% of patients randomized to SIMCOR discontinued therapy due to an adverse event. Flushing episodes (i.e., warmth, redness, itching and/or tingling) were the most common treatment-emergent adverse reactions, occurring in up to 59% of patients treated with SIMCOR. Spontaneous reports with niacin extended-release and clinical studies of SIMCOR suggest that flushing may be accompanied by symptoms of dizziness or syncope, tachycardia, palpitations, shortness of breath, sweating, chills, and/or edema.

### 6.1 Clinical Studies Experience

#### SIMCOR

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

The safety data described below reflect exposure to SIMCOR in 403 patients in a controlled study for a period of 6 months.

*Flushing:* Flushing (warmth, redness, itching and/or tingling) occurred in up to 59% of patients treated with SIMCOR. Flushing resulted in study discontinuation for 6.0% of patients.

*More Common Adverse Reactions:* In addition to flushing, adverse reactions occurring in  $\geq 3\%$  of patients (irrespective of investigator causality) treated with SIMCOR are shown in Table 3 below:

**Table 3. Adverse Reactions Occurring in  $\geq 3\%$  of Patients in a Controlled Clinical Trial**

<b>Adverse Event</b>	<b>SIMCOR overall *</b>	<b>Simvastatin overall **</b>
Total Number of Patients	N=403	N=238
Headache	18 (4.5%)	11 (4.6%)
Pruritus	13 (3.2%)	0 (0.0%)
Nausea	13 (3.2%)	10 (4.2%)
Back Pain	13 (3.2%)	5 (2.1%)
Diarrhea	12 (3.0%)	7 (2.9%)

\* SIMCOR overall included all doses from 500/20 mg to 2000/40 mg

\*\* Simvastatin overall included 20 mg, 40 mg, and 80 mg doses

## **Simvastatin**

In pre-marketing controlled clinical studies and their open extensions (2,423 patients with mean duration of follow-up of approximately 18 months) 1.4% of patients discontinued due to adverse reactions. The most commonly reported adverse reactions (incidence  $> 1\%$ ) in simvastatin controlled clinical trials were: headache (3.5%), abdominal pain (3.5%), constipation (2.3%), upper respiratory infection (2.1%), diarrhea (1.9%), and flatulence (1.9%).

## **Niacin Extended-Release**

In placebo-controlled clinical trials (n=245), flushing episodes were the most common treatment-emergent adverse events (up to 88% of patients) for niacin extended-release. Other adverse events occurring in 5% or greater of patients treated with niacin extended-release are headache (9%),

DN1744V1-Simcor-ADRChange-clean-041508

diarrhea (7%), nausea (5%), rhinitis (5%), and dyspepsia (4%) at a maintenance dose of 1000mg daily.

*Clinical Laboratory Abnormalities:*

**SIMCOR**

Chemistry

Elevations in serum transaminases [*See Warnings and Precautions (5.2)*], CK, fasting glucose, uric acid, alkaline phosphatase, LDH, amylase,  $\gamma$ -glutamyl transpeptidase, bilirubin, and reductions in phosphorus, and abnormal thyroid function tests.

Hematology

Reductions in platelet counts and prolongation of PT. [*See Warnings and Precautions (5.3)*]

**Postmarketing Experience**

Because the below reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Simvastatin**

The following additional adverse reactions have been identified during postapproval use of simvastatin. Hypersensitivity reaction including one or more of the following features: anaphylaxis, angioedema, lupus erythematosus-like syndrome, vasculitis, purpura, thrombocytopenia, leucopenia, hemolytic anemia, positive ANA, ESR increase, eosinophilia, arthritis, photosensitivity, chills, toxic epidermal necrolysis, erythema multiforme, Stevens-Johnson syndrome, urticaria, fever, dyspnea, and arthralgia; pancreatitis, hepatitis, hepatic failure, pruritus, cataracts, polymyositis, dermatomyositis, polymyalgia rheumatica, global amnesia, tendon rupture, peripheral neuropathy, memory impairment.

**NIASPAN**

The following additional adverse reactions have been identified during post-approval use of NIASPAN. Hypersensitivity reaction including one or more of the following features: anaphylaxis, angioedema, urticaria, flushing, dyspnea, tongue edema, larynx edema, face edema, peripheral edema, laryngismus, vesiculobullous rash, palpitations, syncope, hypotension, orthostasis, decreased glucose tolerance, gout, hepatitis, skin discoloration, rhabdomyolysis, amblyopia, and insomnia.

## 7 DRUG INTERACTIONS

No drug interaction studies were conducted with SIMCOR. However, the following interactions have been noted with the individual components of SIMCOR:

### Simvastatin

#### 7.1 CYP3A4 Inhibitors

Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4. Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.

Potent inhibitors of CYP3A4 include:

*Itraconazole, ketoconazole, and other antifungal azoles,*

*Macrolide antibiotics erythromycin, clarithromycin, and telithromycin,*

*HIV protease inhibitors,*

*Antidepressant nefazodone,*

*Grapefruit juice in large quantities (> 1 quart daily).*

Potent inhibitors of CYP3A4 increase the risk of myopathy by reducing the elimination of simvastatin. Hence when simvastatin is used with a potent inhibitor of CYP3A4, elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin. *[See Warnings and Precautions (5.1)]*

Serious skeletal muscle disorder, e.g., rhabdomyolysis, have been reported during concomitant therapy of simvastatin or other HMG-CoA reductase inhibitors with cyclosporine, danazol, itraconazole, ketoconazole, gemfibrozil, niacin, erythromycin, clarithromycin, telithromycin, nefazodone or HIV protease inhibitors.

Concomitant use of drugs labeled as potent inhibitors of CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk. If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with SIMCOR should be suspended during the course of treatment.

#### 7.2 Cyclosporine or Danazol

Although the mechanism is not fully understood, cyclosporine has been shown to increase the area under the curve (AUC) of HMG-CoA reductase inhibitors. The increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4. The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin. *[See Warnings and Precautions (5.1)]*

### **7.3 Amiodarone or Verapamil**

The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin. *[See Warnings and Precautions (5.1)]*

### **7.4 Gemfibrozil and other Fibrates**

Coadministration of gemfibrozil (600 mg twice daily for 3 days) with simvastatin (40 mg daily) resulted in clinically significant increases in simvastatin acid AUC (185%) and peak plasma concentration ( $C_{max}$ , 112%), possibly due to inhibition of simvastatin acid glucuronidation by gemfibrozil. The increase in simvastatin exposure increases the risk of myopathy when coadministered with gemfibrozil. The combined use of SIMCOR with gemfibrozil should be avoided *[See Warnings and Precautions (5.1)]*. The risk of myopathy also increases to a lesser extent when simvastatin is used in combination with other fibrates. Coadministration of 160 mg fenofibrate daily with 80 mg simvastatin daily for 7 days had no effect on plasma AUC (and  $C_{max}$ ) of either total HMG-CoA reductase inhibitory activity or fenofibric acid; there was a modest reduction (approximately 35%) of simvastatin acid which was not considered clinically significant.

### **7.5 Propranolol**

In healthy male volunteers there was a significant decrease in mean  $C_{max}$ , but no change in AUC, for simvastatin total and active inhibitors with concomitant administration of single doses of simvastatin and propranolol. The clinical relevance of this finding is unclear. The pharmacokinetics of the enantiomers of propranolol were not affected.

### **7.6 Digoxin**

Concomitant administration of a single dose of digoxin in healthy male volunteers receiving simvastatin resulted in a slight elevation (less than 0.3 ng/mL) in digoxin concentrations in plasma (as measured by a radioimmunoassay) compared to concomitant administration of placebo and digoxin. Patients taking digoxin should be monitored appropriately when SIMCOR is initiated.

## **7.7 Coumarin Anticoagulants**

In normal volunteers and hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants since the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteers and patients, respectively. With other reductase inhibitors, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly. In such patients, prothrombin time should be determined before starting SIMCOR and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs. Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants. If the dose of SIMCOR is changed or discontinued, the same procedure should be repeated.

## **Niacin**

### **7.8 Aspirin**

Concomitant use of aspirin may decrease the metabolic clearance of niacin. The clinical relevance of this finding is unclear.

### **7.9 Antihypertensive Therapy**

Niacin may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.

### **7.10 Bile Acid Sequestrants**

An *in vitro* study was carried out investigating the niacin-binding capacity of colestipol and cholestyramine. About 98% of available niacin was bound to colestipol, with 10 to 30% binding to cholestyramine. These results suggest that 4 to 6 hours, or as great an interval as possible, should elapse between the ingestion of bile acid-binding resins and the administration of SIMCOR.

### **7.11 Other**

Nutritional supplements containing large doses of niacin or related compounds may potentiate the adverse effects of SIMCOR.

## **8 USE IN SPECIFIC POPULATIONS**

## 8.1 Pregnancy

Pregnancy Category X – [See Contraindications (4)]

SIMCOR is contraindicated in women who are or may become pregnant. Lipid lowering drugs offer no benefit during pregnancy, because cholesterol and cholesterol derivatives are needed for normal fetal development. Serum cholesterol and triglycerides increase during normal pregnancy. Atherosclerosis is a chronic process, and discontinuation of lipid-lowering drugs during pregnancy should have little impact on long-term outcomes of primary hypercholesterolemia therapy. There are no adequate and well-controlled studies of SIMCOR use during pregnancy; however, there are rare reports of congenital anomalies in infants exposed to HMG-CoA reductase inhibitors *in utero*. Animal reproduction studies of simvastatin in rats and rabbits showed no evidence of teratogenicity. SIMCOR may cause fetal harm when administered to a pregnant woman. If SIMCOR is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.

SIMCOR contains simvastatin (a HMG-CoA reductase inhibitor) and niacin (nicotinic acid). There are rare reports of congenital anomalies following intrauterine exposure to HMG-CoA reductase inhibitors. In a review of approximately 100 prospectively followed pregnancies in women exposed to simvastatin or another structurally related HMG-CoA reductase inhibitor, the incidences of congenital anomalies, spontaneous abortions, and fetal deaths/stillbirths did not exceed those expected in the general population. However, the study was only able to exclude a 3- to 4-fold increased risk of congenital anomalies over the background rate. In 89% of these cases, drug treatment was initiated prior to pregnancy and was discontinued during the first trimester when pregnancy was identified. It is not known whether niacin at doses used for lipid disorders can cause fetal harm when administered to a pregnant woman.

Simvastatin was not teratogenic in rats or rabbits at doses that resulted in 3 times the human exposure based on mg/m<sup>2</sup> surface area. However, in studies with another structurally-related HMG-CoA reductase inhibitor, skeletal malformations were observed in rats and mice. Animal reproduction studies have not been conducted with niacin.

Women of childbearing potential, who require SIMCOR treatment for a lipid disorder, should use effective contraception. Patients trying to conceive should contact their prescriber to discuss stopping SIMCOR treatment. If pregnancy occurs, SIMCOR should be immediately discontinued.

## 8.3 Nursing Mothers

DN1744V1-Simcor-ADRChange-clean-041508

It is not known whether simvastatin is excreted into human milk; however, a small amount of another drug in this class does pass into breast milk. Niacin is excreted into human milk but the actual infant dose or infant dose as a percent of the maternal dose is not known. Because of the potential for serious adverse reactions in nursing infants, nursing mothers who require SIMCOR treatment should not breastfeed their infants. A decision should be made whether to discontinue nursing or discontinue drug, taking into account the importance of the drug to the mother. *[see Contraindications (4)].*

#### **8.4 Pediatric Use**

The safety and effectiveness of SIMCOR in pediatric patients have not been established.

#### **8.5 Geriatric Use**

There were 281 (30.8%) patients aged 65 years and older treated with SIMCOR in Phase III clinical studies. No overall differences in safety and effectiveness were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out. A pharmacokinetic study with simvastatin showed the mean plasma level of HMG-CoA reductase inhibitory activity to be approximately 45% higher in elderly patients between 70-78 years of age compared with patients between 18-30 years of age.

#### **8.6 Gender**

Data from the clinical trials suggest that women have a greater hypolipidemic response than men at equivalent doses of niacin extended-release. No consistent gender differences in efficacy and safety were observed in SIMCOR studies.

#### **8.7 Renal Impairment**

No pharmacokinetic studies have been conducted in patients with renal impairment for SIMCOR. Caution should be exercised when SIMCOR is administered to patients with renal disease. For patients with severe renal insufficiency, SIMCOR should not be started unless the patient has already tolerated treatment with simvastatin at a dose of 10 mg or higher. Caution should be exercised when SIMCOR is administered to these patients and they should be closely monitored.

#### **8.8 Hepatic Impairment**

No pharmacokinetic studies have been conducted in patients with hepatic insufficiency for SIMCOR. *[See Warnings and Precautions (5.2)]*



## 10 OVERDOSAGE

Supportive measures should be taken in the event of an overdose. The dialyzability of niacin, or of simvastatin and its metabolites, is not known.


A few cases of overdose with simvastatin have been reported; the maximum dose taken was 3.6 g. All patients recovered without sequelae.

## 11 DESCRIPTION

SIMCOR tablets contain niacin extended-release (NIASPAN) and simvastatin in combination. Simvastatin, an inhibitor of HMG-CoA reductase, and niacin are both lipid-altering agents.

### Niacin Extended-Release


Niacin is nicotinic acid, or 3-pyridinecarboxylic acid. Niacin is a white, nonhygroscopic crystalline powder that is very soluble in water, boiling ethanol, and propylene glycol. It is insoluble in ethyl ether. The empirical formula of niacin is  $C_6H_5NO_2$  and its molecular weight is 123.11. Niacin has the following structural formula:



### Simvastatin

Simvastatin is butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 $\alpha$ ,3 $\alpha$ ,7 $\beta$ ,8 $\beta$ (2S\*4S\*),-8 $\alpha\beta$ ]].

Simvastatin is a white to off-white, nonhygroscopic, crystalline powder that is practically insoluble in water and freely soluble in chloroform, methanol, and ethanol. The empirical formula of simvastatin is  $C_{25}H_{38}O_5$  and its molecular weight is 418.57. Simvastatin has the following structural formula:



DN1744V1-Simcor-ADRChange-clean-041508

SIMCOR is available for oral administration as tablets containing 500 mg of extended-release niacin (NIASPAN) and 20 mg simvastatin (SIMCOR 500/20), 750 mg of extended-release niacin (NIASPAN) and 20 mg simvastatin (SIMCOR 750/20), and 1000 mg of extended-release niacin (NIASPAN) and 20 mg simvastatin (SIMCOR 1000/20). Each tablet contains the following inactive ingredients: hypromellose, povidone, stearic acid, polyethylene glycol, butylated hydroxyanisole, a blue Opadry® color coat (FD&C Blue #2, hypromellose, lactose monohydrate, titanium dioxide, triacetin), and a clear Opadry® coat (hypromellose, polyethylene glycol).

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

#### Niacin

Niacin functions in the body after conversion to nicotinamide adenine dinucleotide (NAD) in the NAD coenzyme system. The mechanism by which niacin alters lipid profiles is not completely understood and may involve several actions, including partial inhibition of release of free fatty acids from adipose tissue, and increased lipoprotein lipase activity (which may increase the rate of chylomicron triglyceride removal from plasma). Niacin decreases the rate of hepatic synthesis of VLDL-C and LDL-C, and does not appear to affect fecal excretion of fats, sterols, or bile acids.

#### Simvastatin

Simvastatin is a prodrug and is hydrolyzed to its active  $\beta$ -hydroxyacid form, simvastatin acid, after administration. Simvastatin is a specific inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in the biosynthetic pathway for cholesterol. In addition, simvastatin reduces VLDL and TG and increases HDL-C.

### 12.2 Pharmacodynamics

A variety of clinical studies have demonstrated that elevated levels of Total-C, LDL-C, and Apo B promote human atherosclerosis. Similarly, decreased levels of HDL-C are associated with the development of atherosclerosis. Epidemiological investigations have established that cardiovascular morbidity and mortality vary directly with the level of Total-C and LDL-C, and inversely with the level of HDL-C.

DN1744V1-Simcor-ADRChange-clean-041508

Like LDL, cholesterol-enriched triglyceride-rich lipoproteins, including VLDL, intermediate-density lipoprotein (IDL), and their remnants, can also promote atherosclerosis. Elevated plasma TG are frequently found in a triad with low HDL-C levels and small LDL particles, as well as in association with non-lipid metabolic risk factors for coronary heart disease (CHD). As such, total plasma TG has not consistently been shown to be an independent risk factor for CHD. Furthermore, the independent effect of raising HDL-C or lowering TG on the risk of coronary and cardiovascular morbidity and mortality has not been determined.

## **SIMCOR**

SIMCOR reduces total-C, LDL-C, non-HDL-C, Apo B, TG, and Lp(a) levels and increases HDL-C in patients with primary type II hyperlipidemia (heterozygous familial and nonfamilial), mixed dyslipidemia, or hypertriglyceridemia.

## **Niacin**

Niacin (but not nicotinamide) in gram doses reduces LDL-C, Apo B, Lp(a), TG, and Total-C, and increases HDL-C. The magnitude of individual lipid and lipoprotein responses may be influenced by the severity and type of underlying lipid abnormality. The increase in HDL-C is associated with an increase in apolipoprotein A-I (Apo A-I) and a shift in the distribution of HDL subfractions. These shifts include an increase in the HDL2:HDL3 ratio, and an elevation in lipoprotein A-I (Lp A-I, an HDL-C particle containing only Apo A-I). Niacin treatment also decreases serum levels of apolipoprotein B-100 (Apo B), the major protein component of the very low-density lipoprotein (VLDL) and LDL fractions, and of Lp(a), a variant form of LDL independently associated with coronary risk. In addition, preliminary reports suggest that niacin causes favorable LDL particle size transformations, although the clinical relevance of this effect requires further investigation.

## **Simvastatin**

Simvastatin reduces elevated total-C, LDL-C, Apo B, and TG, and increases HDL-C in patients with primary heterozygous familial and nonfamilial hypercholesterolemia and mixed dyslipidemia. Simvastatin reduces total-C and LDL-C in patients with homozygous familial hypercholesterolemia. Simvastatin decreases VLDL, total-C/HDL-C ratio, and LDL-C/HDL-C ratio.

## **12.3 Pharmacokinetics**

### **Absorption and Bioavailability**

## **SIMCOR**

The relative bioavailability of niacin (Nicotinuric acid, NUA,  $C_{max}$  and total urinary excretion as the surrogate), simvastatin, and simvastatin acid was evaluated under a light snack conditions in healthy volunteers (n=42), following administration of two 1000/20 mg SIMCOR tablets. Niacin exposure ( $C_{max}$  and AUC) after SIMCOR was similar to that of a niacin extended-release formulation. However, simvastatin and simvastatin acid AUC after SIMCOR increased by 23% and 41%, respectively, compared to those of a simvastatin immediate release formulation. The mean time to  $C_{max}$  ( $T_{max}$ ) for niacin ranged from 4.6 to 4.9 hours and simvastatin from 1.9 to 2.0 hours. Following administration of 2 x 1000/20 mg SIMCOR, the mean  $C_{max}$ ,  $T_{max}$  and  $AUC_{(0-t)}$  for simvastatin acid, active metabolite of simvastatin, were 3.29 ng/mL, 6.56 hours and 30.81 ng.hr/mL respectively.

Bioequivalence has not been evaluated among different SIMCOR dosage strengths. Therefore, dosage strengths of SIMCOR should not be considered exchangeable.

### **Niacin**

Due to extensive and saturable first-pass metabolism, niacin concentrations in the general circulation are dose dependent and highly variable. Peak steady-state niacin concentrations were 0.6, 4.9, and 15.5 mcg/mL after doses of 1000, 1500, and 2000 mg NIASPAN once daily (given as two 500 mg, two 750 mg, and two 1000 mg tablets, respectively). To reduce the risk of gastrointestinal upset, administration of niacin extended-release with a low-fat meal or snack is recommended.

### **Simvastatin**

Since simvastatin undergoes extensive first-pass extraction in the liver, the availability of the drug to the general circulation is low (<5%). Peak plasma concentrations of both active and total inhibitors were attained within 1.3 to 2.4 hours postdose. Following an oral dose of  $^{14}C$ -labeled simvastatin in man, plasma concentration of total radioactivity (simvastatin plus  $^{14}C$ -metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose. Relative to the fasting state, the plasma profile of inhibitors was not affected when simvastatin was administered immediately before an American Heart Association recommended low-fat meal.

### **Metabolism**

#### **SIMCOR**

Following administration of SIMCOR, niacin and simvastatin undergo rapid and extensive first-pass metabolism as described in the following niacin and simvastatin sections. Following administration of 2 x 1000/20 mg SIMCOR in healthy volunteers, 10.2%, 10.7%, and 29.5% of the administered niacin

DN1744V1-Simcor-ADRChange-clean-041508

dose was recovered in urine as niacin metabolites, nicotinuric acid (NUA), N-methylnicotinamide (MNA), and N-methyl-2-pyridone-5-carboxamide (2PY), respectively. Following administration of 2 x 1000/20 mg SIMCOR, the mean  $C_{max}$ ,  $T_{max}$ , and  $AUC_{(0-t)}$  for the simvastatin metabolite, simvastatin acid were 3.29 ng/mL, 6.56 hours, and 30.81 ng·hr/mL respectively.

## Niacin

Niacin undergoes rapid and extensive first-pass metabolism that is dose-rate specific and, at the doses used to treat dyslipidemia, saturable. In humans, one pathway is through a simple conjugation step with glycine to form NUA. NUA is then excreted, although there may be a small amount of reversible metabolism back to niacin. The other pathway results in the formation of nicotinamide adenine dinucleotide (NAD). It is unclear whether nicotinamide is formed as a precursor to, or following the synthesis of, NAD. Nicotinamide is further metabolized to at least MNA and nicotinamide-N-oxide NNO. MNA is further metabolized to two other compounds, 2PY and N-methyl-4-pyridone-5-carboxamide (4PY). The formation of 2PY appears to predominate over 4PY in humans.

## Simvastatin

Simvastatin is a substrate of CYP3A4. Simvastatin is a lactone that is readily hydrolyzed *in vivo* to the corresponding  $\beta$ -hydroxyacid, a potent inhibitor of HMG-CoA reductase. The major active metabolites of simvastatin present in human plasma are the  $\beta$ -hydroxyacid of simvastatin and its 6'-hydroxy, 6'-hydroxymethyl, and 6'-exomethylene derivatives.

## Elimination

### SIMCOR

Following 2 x 1000/20 mg SIMCOR administration, approximately 54% of the niacin dose administered was recovered in urine in 96 hours as niacin and metabolites of which 3.6% was recovered as niacin.

After SIMCOR administration, the mean terminal plasma half-life for simvastatin was 4.2 to 4.9 hours and for simvastatin acid was 4.6 to 5.0 hours.

## Niacin

Niacin and its metabolites are rapidly eliminated in the urine. Following single and multiple doses of 1500 to 2000 mg niacin, approximately 53 to 77% of the niacin dose administered as NIASPAN was recovered in urine as niacin and metabolites; up to 7.7% of the dose was recovered in urine as

DN1744V1-Simcor-ADRChange-clean-041508

unchanged niacin after multiple dosing with 2 x 1000 mg NIASPAN. The ratio of metabolites recovered in the urine was dependent on the dose administered.

### **Simvastatin**

Simvastatin is excreted in urine, based on studies in humans. Following an oral dose of <sup>14</sup>C-labeled simvastatin in man, 13% of the dose was excreted in urine and 60% in feces.

### **Special Populations**

A pharmacokinetic study with simvastatin showed the mean plasma level of HMG-CoA reductase inhibitory activity to be approximately 45% higher in elderly patients between 70-78 years of age compared with patients between 18-30 years of age.

Steady-state plasma concentrations of niacin and metabolites after administration of niacin extended-release are generally higher in women than in men, with the magnitude of the difference varying with dose and metabolite. Recovery of niacin and metabolites in urine, however, is generally similar for men and women, indicating that absorption is similar for both genders. The gender differences observed in plasma levels of niacin and its metabolites may be due to gender-specific differences in metabolic rate or volume of distribution.

Pharmacokinetic studies with a statin having a similar principal route of elimination to that of simvastatin have suggested that for a given dose level, higher systemic exposure may be achieved in patients with severe renal insufficiency (as measured by creatinine clearance).

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

No studies have been conducted with SIMCOR regarding carcinogenesis, mutagenesis, or impairment of fertility.

#### **Niacin**

Niacin, administered to mice for a lifetime as a 1% solution in drinking water, was not carcinogenic. The mice in this study received approximately 6 to 8 times a human dose of 3000 mg/day as determined on a mg/m<sup>2</sup> basis. Niacin was negative for mutagenicity in the Ames test. No studies on impairment of fertility have been performed.

#### **Simvastatin**

DN1744V1-Simcor-ADRChange-clean-041508

In a 72-week carcinogenicity study, mice were administered daily doses of simvastatin of 25, 100, and 400 mg/kg body weight, which resulted in mean plasma drug levels approximately 1, 4, and 8 times higher than the mean human plasma drug level, respectively (as total inhibitory activity based on AUC) after an 80-mg oral dose. Liver carcinomas were significantly increased in high-dose females and mid- and high-dose males with a maximum incidence of 90% in males. The incidence of adenomas of the liver was significantly increased in mid- and high-dose females. Drug treatment also significantly increased the incidence of lung adenomas in mid- and high-dose males and females. Adenomas of the Harderian gland (a gland of the eye of rodents) were significantly higher in high-dose mice than in controls. No evidence of a tumorigenic effect was observed at 25 mg/kg/day.

In a separate 92-week carcinogenicity study in mice at doses up to 25 mg/kg/day, no evidence of a tumorigenic effect was observed (mean plasma drug levels were 1 times higher than humans given 80 mg simvastatin as measured by AUC). In a two-year study in rats at 25 mg/kg/day, there was a statistically significant increase in the incidence of thyroid follicular adenomas in female rats exposed to approximately 11 times higher levels of simvastatin than in humans given 80 mg simvastatin (as measured by AUC). A second two-year rat carcinogenicity study with doses of 50 and 100 mg/kg/day produced hepatocellular adenomas and carcinomas (in female rats at both doses and in males at 100 mg/kg/day). Thyroid follicular cell adenomas were increased in males and females at both doses; thyroid follicular cell carcinomas were increased in females at 100 mg/kg/day. The increased incidence of thyroid neoplasms appears to be consistent with findings from other HMG-CoA reductase inhibitors. These treatment levels represented plasma drug levels (AUC) of approximately 7 and 15 times (males) and 22 and 25 times (females) the mean human plasma drug exposure after an 80 milligram daily dose. No evidence of mutagenicity was observed in a microbial mutagenicity (Ames) test with or without rat or mouse liver metabolic activation. In addition, no evidence of damage to genetic material was noted in an *in vitro* alkaline elution assay using rat hepatocytes, a V-79 mammalian cell forward mutation study, an *in vitro* chromosome aberration study in CHO cells, or an *in vivo* chromosomal aberration assay in mouse bone marrow. There was decreased fertility in male rats treated with simvastatin for 34 weeks at 25 mg/kg body weight (4 times the maximum human exposure level, based on AUC, in patients receiving 80 mg/day); however, this effect was not observed during a subsequent fertility study in which simvastatin was administered at this same dose level to male rats for 11 weeks (the entire cycle of spermatogenesis including epididymal maturation). No microscopic changes were observed in the testes of rats from either study. At 180 mg/kg/day, (which produces exposure levels 22 times higher than those in humans taking 80 mg/day based on surface area, mg/m<sup>2</sup>), seminiferous tubule degeneration (necrosis and loss of spermatogenic

DN1744V1-Simcor-ADRChange-clean-041508

epithelium) was observed. In dogs, there was drug-related testicular atrophy, decreased spermatogenesis, spermatocytic degeneration and giant cell formation at 10 mg/kg/day, (approximately 2 times the human exposure, based on AUC, at 80 mg/day). The clinical significance of these findings is unclear.

## **13.2 Animal Toxicology and/or Pharmacology**

### **SIMCOR**

No animal toxicology or pharmacology studies were done with SIMCOR.

### **Niacin**

No animal toxicology or pharmacology studies were done with niacin extended-release.

### **Simvastatin**

Optic nerve degeneration was seen in clinically normal dogs treated with simvastatin for 14 weeks at 180 mg/kg/day, a dose that produced mean plasma drug levels about 12 times higher than the mean plasma drug level in humans taking 80 mg/day. A chemically similar drug in this class also produced optic nerve degeneration (Wallerian degeneration of retinogeniculate fibers) in clinically normal dogs in a dose-dependent fashion starting at 60 mg/kg/day, a dose that produced mean plasma drug levels about 30 times higher than the mean plasma drug level in humans taking the highest recommended dose (as measured by total enzyme inhibitory activity). This same drug also produced vestibulocochlear Wallerian-like degeneration and retinal ganglion cell chromatolysis in dogs treated for 14 weeks at 180 mg/kg/day, a dose that resulted in a mean plasma drug level similar to that seen with the 60 mg/kg/day dose.

Central Nervous System (CNS) vascular lesions, characterized by perivascular hemorrhage and edema, mononuclear cell infiltration of perivascular spaces, perivascular fibrin deposits and necrosis of small vessels were seen in dogs treated with simvastatin at a dose of 360 mg/kg/day, a dose that produced mean plasma drug levels that were about 14 times higher than the mean plasma drug levels in humans taking 80 mg/day. Similar CNS vascular lesions have been observed with several other drugs of this class.

There were cataracts in female rats after two years of simvastatin treatment with 50 and 100 mg/kg/day (22 and 25 times the human AUC at 80 mg/day, respectively) and in dogs after three months at 90 mg/kg/day (19 times) and at two years at 50 mg/kg/day (5 times).



## Reproductive Toxicology Studies

Simvastatin was not teratogenic in rats at doses of 25 mg/kg/day or in rabbits at doses up to 10 mg/kg/day. These doses resulted in 3 times (rat) or 3 times (rabbit) the human exposure based on mg/m<sup>2</sup> surface area. However, in studies with another structurally-related HMG-CoA reductase inhibitor, skeletal malformations were observed in rats and mice.

## 14 CLINICAL STUDIES

### 14.1 Modifications of Lipid Profiles

#### SIMCOR

In a double-blind, randomized, multicenter, multi-national, active-controlled, 24-week study, the lipid effects of SIMCOR were compared to simvastatin 20 mg and 80 mg in 641 patients with type II hyperlipidemia or mixed dyslipidemia. Following a lipid qualification phase, patients were eligible to enter one of two treatment groups. In Group A, patients on simvastatin 20 mg monotherapy, with elevated non-HDL levels and LDL-C levels at goal per the NCEP guidelines, were randomized to one of three treatment arms: SIMCOR 1000/20 mg, SIMCOR 2000/20 mg, or simvastatin 20 mg. In Group B, patients on simvastatin 40 mg monotherapy, with elevated non-HDL levels per the NCEP guidelines regardless of attainment of LDL-C goals, were randomized to one of three treatment arms: SIMCOR 1000/40 mg, SIMCOR 2000/40 mg, or simvastatin 80 mg. Therapy was initiated at the 500 mg dose of SIMCOR and increased by 500 mg every four weeks. Thus patients were titrated to the 1000 mg dose of SIMCOR after four weeks and to the 2000 mg dose of SIMCOR after 12 weeks. All patients randomized to simvastatin monotherapy received 50 mg immediate-release niacin daily in an attempt to keep the study from becoming unblinded due to flushing in the SIMCOR groups. Patients were instructed to take one 325 mg aspirin or 200 mg ibuprofen 30 minutes prior to taking the double-blind medication to help minimize flushing effects.

In Group A, the primary efficacy analysis was a comparison of the mean percent change in non-HDL levels between the SIMCOR 2000/20 mg and simvastatin 20 mg groups, and if statistically significant, then a comparison was conducted between the SIMCOR 1000/20 mg and simvastatin 20 mg groups. In Group B, the primary efficacy analysis was a determination of whether the mean percent change in non-HDL in the SIMCOR 2000/40 mg group was non-inferior to the mean percent change in the simvastatin 80 mg group, and if so, whether the mean percent change in non-HDL in the SIMCOR 1000/40 mg group was non-inferior to the mean percent change in the simvastatin 80 mg group.

In Group A, the non-HDL-C lowering with SIMCOR 2000/20 and SIMCOR 1000/20 was statistically significantly greater than that achieved with simvastatin 20 mg after 24 weeks ( $p < 0.05$ ; Table 4). The completion rate after 24 weeks was 72% for the SIMCOR arms and 88% for the simvastatin 20 mg arm. In Group B, the non-HDL-C lowering with SIMCOR 2000/40 and SIMCOR 1000/40 was non-inferior to that achieved with simvastatin 80 mg after 24 weeks (Table 5). The completion rate after 24 weeks was 78% for the SIMCOR arms and 80% for the simvastatin 80 mg arm.

SIMCOR was not superior to simvastatin in lowering LDL-C in either Group A or Group B. However, SIMCOR was superior to simvastatin in both groups in lowering TG and raising HDL (Tables 6 and 7).

**Table 4. Non-HDL Treatment Response Following 24-Week Treatment Mean Percent Change from Simvastatin 20-mg Treated Baseline**

Group A									
Week	Simcor 2000/20			Simcor 1000/20			Simvastatin 20		
	n <sup>a</sup>	dose (mg/mg)	non-HDL <sup>b</sup> mg/dL	n <sup>a</sup>	Dose (mg/mg)	non-HDL <sup>b</sup> mg/dL	n <sup>a</sup>	Dose (mg/mg)	non-HDL <sup>b</sup> mg/dL
Baseline	56	---	163.1	108	---	164.8	102	---	163.7
4	52	500/20	-12.9%	86	500/20	-12.8%	91	20	-8.3%
8	46	1000/20	-17.5%	91	1000/20	-15.5%	95	20	-8.3%
12	46	1500/20	-18.9%	90	1000/20	-14.8%	96	20	-6.4%
24	40	2000/20	-19.5% <sup>†</sup>	78	1000/20	-13.6% <sup>†</sup>	90	20	-5.0%
Dropouts by week 24:	28.6%			27.8%			11.8%		

<sup>a</sup> n=number of subjects with values in the analysis window at each timepoint

<sup>b</sup> The percent change from baseline is the model-based mean from a repeated measures mixed model with no imputation for missing data from study dropouts.

<sup>†</sup> significant vs. simvastatin 20 mg at the primary endpoint (Week 24),  $p < 0.05$

**Table 5. Non-HDL Treatment Response Following 24-Week Treatment Mean Percent Change from Simvastatin 40-mg Treated Baseline**

Group B									
Week	Simcor 2000/40			Simcor 1000/40			Simvastatin 80		
	n <sup>a</sup>	dose (mg/mg)	non-HDL <sup>b</sup> mg/dL	n <sup>a</sup>	Dose (mg/mg)	non-HDL <sup>b</sup> mg/dL	n <sup>a</sup>	Dose (mg/mg)	non-HDL <sup>b</sup> mg/dL
Baseline	98	---	144.4	111	---	141.2	113	---	134.5

DN1744V1-Simcor-ADRChange-clean-041508

4	96	500/40	-6.0%	108	500/40	-5.9%	110	80	-11.3%
8	93	1000/40	-15.5%	100	1000/40	-16.2%	104	80	-13.7%
12	90	1500/40	-18.4%	97	1000/40	-12.6%	100	80	-9.5%
24	80	2000/40	-7.6% <sup>c</sup>	82	1000/40	-6.7% <sup>d</sup>	90	80	-6.0%
Dropouts by week	18.4%			26.1%			20.4%		

24:

<sup>a</sup> n=number of subjects with values in the analysis window at each timepoint

<sup>b</sup> The percent change from baseline is the model-based mean from a repeated measures mixed model with no imputation for missing data from study dropouts.

<sup>c</sup> non-inferior to Simvastatin 80 arm; 95% confidence interval of mean difference in non-HDL for Simcor 2000/40 vs. Simvastatin 80 is (-7.7%, 4.5%)

<sup>d</sup> non-inferior to Simvastatin 80 arm; 95% confidence interval of mean difference in non-HDL for Simcor 1000/40 vs. Simcor 80 is (-6.6%, 5.3%)

**Table 6. Mean Percent Change from Baseline to Week 24 in Lipoprotein Lipid Levels**

TREATMENT	N	Treatment Group A				
		LDL-C	Total-C	HDL-C	TG <sup>a</sup>	Apo B
Baseline (mg/dL)*	266	120	207	43	209	102
Simvastatin 20 mg	102	-6.7%	-4.5%	7.8%	-15.3%	-5.6%
SIMCOR 1000/20	108	-11.9%	-8.8%	20.7%	-26.5%	-13.2%
SIMCOR 2000/20	56	-14.3%	-11.1%	29.0%	-38.0%	-18.5%

\* either treatment naïve or after receiving simvastatin 20 mg

<sup>a</sup> medians are reported for TG

**Table 7. Mean Percent Change from Baseline to Week 24 in Lipoprotein Lipid Levels**

TREATMENT	N	Treatment Group B				
		LDL-C	Total-C	HDL-C	TG <sup>a</sup>	Apo B
Baseline (mg/dL)*	322	108	187	47	145	93
Simvastatin 80 mg	113	-11.4%	-6.2%	0.1%	0.3%	-7.5%
SIMCOR	111	-7.1%	-3.1%	15.4%	-22.8%	-7.7%

## DN1744V1-Simcor-ADRChange-clean-041508

1000/40

SIMCOR 98 -5.1% -1.6% 24.4% -31.8% -10.5%

2000/40

\* after receiving simvastatin 40 mg

<sup>a</sup> medians are reported for TG

---

### Limitations of use

No incremental benefit of SIMCOR on cardiovascular morbidity and mortality over and above that demonstrated for simvastatin monotherapy and niacin monotherapy has been established.

### 16 HOW SUPPLIED/STORAGE AND HANDLING

SIMCOR tablets are available as blue, unscored, tablets, packaged in bottles of 90 tablets. Each tablet has “KOS” debossed on one side and a code number specific to the tablet strength on the other. Please see the table below:

SIMCOR Tablet Strength	Debossed ID	NDC Number
500mg/20mg	KOS/021	0074-3312-90
750mg/20mg	KOS/022	0074-3315-90
1000mg/20mg	KOS/023	0074-3316-90

Storage: Store at controlled room temperature 20°-25°C (68°-77°F).

### 17 PATIENT COUNSELING INFORMATION

The patient should be informed of the following:

#### 17.1 Dosing Time

SIMCOR tablets should be taken at bedtime, after a low-fat snack. Administration on an empty stomach is not recommended.

#### 17.2 Tablet Integrity

SIMCOR tablets should not be broken, crushed or chewed, but should be swallowed whole.

#### 17.3 Dosing Interruption

If dosing is interrupted for any length of time, their physician should be contacted prior to re-starting therapy; re-titration is recommended.

#### **17.4 Muscle Pain**

To notify their physician of any unexplained muscle pain, tenderness, or weakness promptly. The risk of this occurring is increased when taking certain types of medication or consuming larger quantities of grapefruit juice. They should discuss all medication, both prescription and over the counter, with their physician.

#### **17.5 Flushing**

Flushing is a common side effect of niacin therapy that may subside after several weeks of consistent SIMCOR use. Flushing may vary in severity and is more likely to occur with initiation of therapy, or during dose increases. By dosing at bedtime, flushing will most likely occur during sleep. However, if awakened by flushing at night, the patient should get up slowly, especially if feeling dizzy, feeling faint, or taking blood pressure medications.

#### **17.6 Use of Aspirin or other Non-Inflammatory Medication**

Taking aspirin or non-steroidal anti-inflammatory medications (e.g., ibuprofen) approximately 30 minutes before dosing can minimize flushing.

#### **17.7 Diet**

To avoid ingestion of alcohol, hot beverages and spicy foods around the time of taking SIMCOR to minimize flushing.

#### **17.8 Supplements**

To notify their physician if they are taking vitamins or other nutritional supplements containing niacin or nicotinamide.

#### **17.9 Dizziness**

To notify their physician if symptoms of dizziness occur.

#### **17.10 Diabetics**

If diabetic, to notify their physician of changes in blood glucose.

### 17.11 Pregnancy

Women of childbearing age should use an effective method of birth control to prevent pregnancy while using SIMCOR. Discuss future pregnancy plans with your healthcare professional, and discuss when to stop SIMCOR if you are trying to conceive. If you are pregnant, stop SIMCOR and call your healthcare professional.

### 17.12 Breastfeeding

Women who are breastfeeding should not use SIMCOR. If you have a lipid disorder and are breastfeeding, speak with your healthcare professionals about your lipid disorder and whether or not you should breastfeed your infant.

## SIMCOR (simvastatin/niacin extended-release)

PRODUCT INFO			
Product Code	0074-3316	Dosage Form	TABLET, FILM COATED, EXTENDED RELEASE
Route Of Administration	ORAL	DEA Schedule	
INGREDIENTS			
Name (Active Moiety)	Type	Strength	
simvastatin	Active	20 MILLIGRAM In 1 TABLET	
niacin extended-release	Active	1000 MILLIGRAM In 1 TABLET	
hypromellose	Inactive		
povidone	Inactive		
stearic acid	Inactive		
polyethylene glycol	Inactive		
Blue Opadry II 32K-10858	Inactive		
butylated hydroxyanisole	Inactive		
IMPRINT INFORMATION			
Characteristic	Appearance	Characteristic	Appearance

DN1744V1-Simcor-ADRChange-clean-041508

<b>Color</b>	BLUE	<b>Score</b>	1
<b>Shape</b>	CAPSULE	<b>Symbol</b>	false
<b>Imprint Code</b>	KOS;023	<b>Coating</b>	true
<b>Size</b>	17mm		

**PACKAGING**

#	NDC	Package Description	Multilevel Packaging
1	0074-3316-90	90 TABLET In 1 BOTTLE (1 BOTTLE)	None

**SIMCOR (simvastatin/niacin extended-release)**

**PRODUCT INFO**

<b>Product Code</b>	0074-3315	<b>Dosage Form</b>	TABLET, FILM COATED, EXTENDED RELEASE
<b>Route Of Administration</b>	ORAL	<b>DEA Schedule</b>	

**INGREDIENTS**

Name (Active Moiety)	Type	Strength
simvastatin	Active	20 MILLIGRAM In 1 TABLET
niacin extended-release	Active	750 MILLIGRAM In 1 TABLET
hypromellose	Inactive	
povidone	Inactive	
stearic acid	Inactive	
polyethylene glycol	Inactive	
Blue Opadry II 32K-10858	Inactive	
butylated hydroxyanisole	Inactive	

**IMPRINT INFORMATION**

Characteristic	Appearance	Characteristic	Appearance
----------------	------------	----------------	------------

DN1744V1-Simcor-ADRChange-clean-041508

<b>Color</b>	BLUE	<b>Score</b>	1
<b>Shape</b>	CAPSULE	<b>Symbol</b>	false
<b>Imprint Code</b>	KOS;022	<b>Coating</b>	true
<b>Size</b>	17mm		

**PACKAGING**

#	NDC	Package Description	Multilevel Packaging
1	0074-3315-90	90 TABLET In 1 BOTTLE (1 BOTTLE)	None

**SIMCOR (simvastatin/niacin extended-release)**

**PRODUCT INFO**

<b>Product Code</b>	0074-3312	<b>Dosage Form</b>	TABLET, FILM COATED, EXTENDED RELEASE
<b>Route Of Administration</b>	ORAL	<b>DEA Schedule</b>	

**INGREDIENTS**

Name (Active Moiety)	Type	Strength
simvastatin	Active	20 MILLIGRAM In 1 TABLET
niacin extended-release	Active	500 MILLIGRAM In 1 TABLET
hypromellose	Inactive	
povidone	Inactive	
stearic acid	Inactive	
polyethylene glycol	Inactive	
Blue Opadry II 32K-10858	Inactive	
butylated hydroxyanisole	Inactive	

**IMPRINT INFORMATION**

Characteristic	Appearance	Characteristic	Appearance
----------------	------------	----------------	------------



DN1744V1-Simcor-ADRChange-clean-041508

<b>Color</b>	BLUE	<b>Score</b>	1
<b>Shape</b>	CAPSULE	<b>Symbol</b>	false
<b>Imprint Code</b>	KOS;021	<b>Coating</b>	true
<b>Size</b>	17mm		
<b>PACKAGING</b>			
<b>#</b>	<b>NDC</b>	<b>Package Description</b>	<b>Multilevel Packaging</b>
1	0074-3312-90	90 TABLET In 1 BOTTLE (1 BOTTLE)	None

Abbott Laboratories, Inc.